Shares in Neurizon Therapeutics Ltd (ASX: NUZ) are down about 45% over the past 12 months, but according to the team at Morgans, there is potentially good upside in the stock.

Key hire a positive sign

Morgans has just released a new research report on the company and reiterated its bullish share price target on the company, which I’ll get to shortly.

The broker has revisited Neurizon because the company released three news announcements in quick succession earlier this month.

Arguably, the most impactful of these was the hiring of a new Chief Executive Officer, Dr Chris Bremer, who has more than 20 years’ leadership experience spanning drug development, portfolio strategy, commercialisation, and business development.

Neurizon said that during his career, Dr Bremer had been involved in more than US$1 billion worth of licensing transactions.

The company said:

He has extensive experience guiding pharmaceutical assets from early development through to product launch and lifecycle management, as well as evaluating and executing licensing and strategic partnership transactions. His appointment comes as Neurizon advances NUZ-001 through Regimen I of the registrational Phase 2/3 HEALEY ALS Platform Trial and enters the important period leading up to topline results, expected in late Q2 CY2027. His combination of scientific, medical, commercial and transactional experience is particularly relevant as the Company prepares for the potential regulatory, development and strategic pathways that may follow and seeks to create long term shareholder value.

Neurizon’s lead investigational therapy, NUZ-001, is being evaluated as a treatment for ALS in 250 participants.

The company said its priorities “include disciplined execution of the clinical program through to topline results, continued regulatory … readiness, further development of the scientific evidence supporting NUZ-001, and preparation for potential development, partnering and commercial pathways, subject to the outcomes of the study”.

Shares looking cheap according to Morgans

Morgans said they saw Dr Bremer’s hiring as a signal that the company was looking to find development partners.

They said:

The company is unlikely to recruit a US$1bn-plus licensing operator two quarters from a registrational readout unless the Board is building toward that outcome as the preferred path. Dr Bremer has worked both sides of the licensing fence, inbound and outbound, so his skillset should be useful in structuring the dataroom, shaping the partnering process and negotiating economics if the topline result is positive.

Morgans has a price target on Neurizon of 20 cents per share compared to the current share price of 7.5 cents.

Their totally unrisked valuation is $1.50 per share, while should the clinical trial be a failure, the valuation drops to 1 to 2 cents.

Neurizon is valued at $59.4 million.    

The post Could this ASX biotech really jump more than 150%? One broker thinks so appeared first on The Motley Fool Australia.

More reading

• Why did the Bitcoin price just plunge 6%?
• How much passive income could I earn from a $650,000 superannuation balance?
• Down 6% today: What’s going on with the James Hardie share price?
• JB Hi-Fi vs Harvey Norman: Which dividend stock wins?
• Why this ASX share is a retiree’s dream for FY27

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The ASX share Charter Hall Long WALE REIT (ASX: CLW) looks to me like a top pick for retirees and anyone wanting passive income.

Commercial property typically offers a much higher rental yield than residential property, allowing it to provide investors with attractive passive income.

Real estate investment trusts (REITs) are the structure that allows investors to invest in commercial property on the ASX.

For me, Charter Hall Long WALE REIT is one of the leading picks for retirees for a number of reasons.

Diversification

The business can offer investors significant diversification because it’s invested across a number of key defensive tenant industries that are supposedly resilient to economic shocks.

It’s invested in areas that have tenants across government areas (like Geosciences Australia), hotels, grocery and distribution, telecommunications exchanges, data centres, service stations, banking and professional services, food manufacturing, healthcare, Bunnings properties, and more.

To be able to make one investment and get exposure to all of those sectors sounds appealing to me.

In terms of the quality of tenants, the organisations that account for at least 5% of revenue include government entities, Endeavour Group Ltd (ASX: EDV), Telstra Group Ltd (ASX: TLS), BP, Coles Group Ltd (ASX: COL) and Metcash Ltd (ASX: MTS).

The tenants are signed on for long-term contracts, giving investors long-term income security. Charter Hall Long WALE REIT currently has a weighted average lease expiry (WALE) of around nine years, which is a comforting length of time for retirees.

Ongoing rental growth

A REIT is not a term deposit; it’s capable of delivering growth for investors.

The business has rental growth built into its contracts, which is a good tailwind for both rising property values and increasing the distribution over time.

Some of the properties have rental income growth linked to inflation, while the rest have fixed annual increases. This combination helped the business achieve average annual net property income growth of 3.1% in FY26.

I think rising rental income is a key factor that helped the business report a 2.6% year-over-year improvement in net tangible assets (NTA) during FY26.

Strong passive income yield

The business has a very generous distribution payout ratio of 100% of its rental earnings, giving investors a large yield.

It’s also trading at a large discount to its underlying value – the NTA was $4.71 as of 30 June 2026. That means it’s trading at a 28% discount, which is enormous for a high-quality REIT, in my view.

The ASX share expects to pay an annual distribution of 25.5 cents per security in FY27, which translates into a distribution yield of 7.5%. I think that’s very appealing, and I’d happily buy some units if I were a retiree.

The post Why this ASX share is a retiree’s dream for FY27 appeared first on The Motley Fool Australia.

More reading

• How to make $26,000 of passive income from ASX shares
• How much is needed in superannuation to target a $6,500 monthly passive income?
• How much superannuation is needed to target $5,500 per month in passive income?
• How much is needed in superannuation to target a $70,000 annual passive income?
• 2 ASX blue-chip shares offering big dividend yields

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended BP. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

With proposed changes to Australian tax laws on negative gearing and capital gains, ASX shares with large dividend yields could be much more appealing to investors.

I think there’s something very satisfying about seeing cash paid into my bank account regularly by ASX dividend shares. If we choose the right investments, Aussies can enjoy larger dividend payments over time.

Huge dividend yields of more than 10% aren’t seen as safe payouts. There’s normally a reason the yield is that high – earnings may soon fall and/or the dividend payout ratio is too high.

But there are a couple of names that are providing investors with dividend yields of more than 10%, and those payouts may well be sustainable going forward. I’m a fan of the two names below.

Shaver Shop Group Ltd (ASX: SSG)

This ASX share describes itself as an Australian and New Zealand specialty retailer of male and female personal grooming products, and aspires to be the market leader in ‘all things related to hair removal’.

It currently has 127 stores across Australia and New Zealand, selling a wide range of quality products at competitive prices. Thanks to its position in the market, it has managed to negotiate exclusive products with certain suppliers.

The main product types it sells are electric shavers, clippers, trimmers, and wet shave items. It also sells other items, including oral care, hair care, massage, air treatment, and beauty categories.

The business trades on a low P/E ratio and has a generous dividend payout ratio, leading to an impressive dividend yield. It generated 11.3 cents of earnings per share (EPS) in FY26 and paid an annual dividend per share of 10.3 cents.

Its FY26 payout translates into a grossed-up dividend yield of 11.4%, which is an excellent yield considering the payout has grown or been maintained every year since 2017.

I think the move to grow its own brand, called Transform-U, is smart because it fills gaps in the company’s overall product offering, provides compelling customer value, and can lead to a stronger gross profit margin. Transform-U represented 8% of total sales in FY26, up from 3.4% in FY25.

Hearts and Minds Investments Ltd (ASX: HM1)

The other ASX share I want to highlight with a huge dividend yield is Hearts and Minds, a listed investment company (LIC) with a philanthropic cause.

Instead of paying management fees to fund managers, the LIC donates a small portion of its net assets each year to medical research in Australia. I think that’s a great initiative.

The portfolio is decided in two different ways. A majority of the portfolio is invested by a group of core portfolio managers on an ongoing basis.

The rest of the portfolio’s picks are decided at an annual investment conference. Investment professionals pitch their best pick, and each of those is also part of the portfolio.

Most of the portfolio is normally invested in global shares, which can provide Aussies with useful diversification.

The LIC has grown its half-yearly dividend by 0.5 cents every six months in recent history. Assuming it continues that record, the next two dividends to be paid will amount to 20.5 cents per share, which is a grossed-up dividend yield of 10.4%, including franking credits.

The post 2 ASX shares with dividend yields above 10% appeared first on The Motley Fool Australia.

More reading

• How much is needed in superannuation to target a $6,500 monthly passive income?
• How much superannuation is needed to target $5,500 per month in passive income?
• How much is needed in superannuation to target a $70,000 annual passive income?
• How much is needed in superannuation to target a $60,000 annual passive income?
• 2 ASX shares with dividend yields above 9.5%

Motley Fool contributor Tristan Harrison has positions in Hearts And Minds Investments. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Shaver Shop Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.